Open AccessNeprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
Author(s) -
Domenico Acanfora,
Marco Matteo Ciccone,
Pietro Scicchitano,
Chiara Acanfora,
Gerardo Casucci
Publication year - 2020
Publication title -
european heart journal - cardiovascular pharmacotherapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.895
H-Index - 26
eISSN - 2055-6845
pISSN - 2055-6837
DOI - 10.1093/ehjcvp/pvaa028
Subject(s) - sacubitril, valsartan , valsartan , neprilysin , sacubitril , angiotensin receptor , pharmacology , covid-19 , medicine , receptor , virology , angiotensin ii , chemistry , blood pressure , enzyme , disease , outbreak , infectious disease (medical specialty) , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom